Add BrightSurf on Google Email

An eventful year in pharma

The pharmaceutical industry made significant strides in 2020, developing tests, therapeutics, and vaccines to combat COVID-19. Companies like Eli Lilly and Regeneron led the way in making antibody therapies, while Moderna used messenger RNA to develop a potential vaccine with promising early trial data.

SourceAmerican Chemical Society·JournalChemical & Engineering News·DateDec 9, 2020

Nursing researcher's experience in COVID-19 vaccine trial

A nursing researcher reflects on her experience participating in a COVID-19 vaccine trial, discussing the importance of informing patients about possible side effects. The article emphasizes the need for clinicians to prepare their patients for vaccination, ensuring informed consent and minimizing adverse reactions.

SourceJAMA Network·JournalJAMA Internal Medicine·DateDec 7, 2020

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines

The article emphasizes the importance of conducting rigorous evaluation to ensure COVID-19 vaccine safety and efficacy. Historical experience with vaccine development informs regulatory practices, including pre-licensure monitoring for rare adverse events and post-licensure pauses if serious adverse events are detected.

'Meet people where they are:' local health departments key to hepatitis B vaccination

A West Virginia University study suggests that local health departments are crucial in getting the hepatitis B vaccine to those who need it most, particularly individuals at risk of contracting the virus. The study found that partnerships between health departments and local drug treatment programs significantly increased vaccine compl...

SourceWest Virginia University·JournalAmerican Journal of Preventive Medicine·DateNov 17, 2020

Safety of HPV vaccines in males

New analysis shows HPV vaccines are safe for males, with similar side effects to females. The study evaluated reports of adverse events from the U.S. Vaccine Adverse Event Reporting System between 2006 and 2018.

SourceWiley·JournalBritish Journal of Clinical Pharmacology·DateNov 4, 2020

The Lancet Infectious Diseases: Experts outline key challenges for assessing clinical efficacy of COVID-19 vaccines

Researchers stress the need for standardised methods to assess COVID-19 vaccine efficacy, highlighting challenges in determining severe disease protection and the importance of long-term follow-up. Controlled human infection studies may offer rapid assessment but predictability for older adults remains unclear.

SourceThe Lancet·JournalThe Lancet Infectious Diseases·DateOct 27, 2020

US adults' likelihood of accepting COVID-19 vaccination

A survey study of US adults found that vaccine-related attributes and political characteristics are associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine. The results may inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available.

SourceJAMA Network·JournalJAMA Network Open·DateOct 20, 2020

The Lancet Infectious Diseases: Preliminary results find vaccine candidate based on inactivated SARS-CoV-2 virus is safe and induces an immune response in healthy volunteers

A Phase 1/2 randomised controlled trial found the vaccine candidate BBIBP-CorV is safe and induces an immune response in healthy volunteers. The study detected antibody responses in all recipients by day 42 after vaccination, and was well-tolerated with no severe adverse reactions reported.

SourceThe Lancet·JournalThe Lancet Infectious Diseases·DateOct 15, 2020